We are delighted to welcome Click Therapeutics as a Strategic Partner for Frontiers Health 2025. 

Click Therapeutics, Inc., operating at the intersection of biology and technology, uses a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click has received three FDA marketing authorizations: CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine; Rejoyn™, co-developed with Otsuka, the first FDA-authorized digital therapeutic for adjunctive treatment of major depressive disorder; and AspyreRx, authorized for type 2 diabetes. Building on its platform, the company also launched Click SE™, pioneering Software-Enhanced Drug™ therapies that combine digital interventions with pharmacotherapy. 

Driven by a multidisciplinary team and a mission to transform patient care, Click continues to advance the frontiers of cognitive, behavioral, and neuromodulatory innovation. 

Discover what’s next in digital therapeutics with Click Therapeutics at FH25.

Meet the team at their reserved networking lounge and explore partnership opportunities.